Skip to main content

Share story

Security

ZDI-26-217

A vulnerability known as ZDI-26-217 allows remote attackers to execute arbitrary code on affected installations of GIMP. User interaction is required to exploit the issue in that the target must visit a malicious page or open a malicious file. The flaw occurs within the parsing of PSD files. It stems from the lack of proper validation of user supplied data, which can result in an integer overflow before allocating a buffer. An attacker can use the vulnerability to execute code in the context of the current process. GIMP has issued an update to correct the vulnerability. More details can be found at the commit on the GNOME GitLab repository. The disclosure timeline shows the vulnerability was reported to the vendor on 2026-03-05 with a coordinated public release of the advisory on 2026-03-19. The advisory was also updated on 2026-03-19. Credit goes to an anonymous researcher.
Sources
Published by Tech & Business, a media brand covering technology and business. This story was sourced from Zero Day Initiative and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.